Tag Archive for: Alentis Therapeutics

Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics to advance groundbreaking antibody-drug conjugates (ADCs) for solid tumours

/in

Funding to support development of first-in-class CLDN1 targeted medicines Strong syndicate of international life science investors One of the largest ADC-focused private fundraisings globally in 2024 Copenhagen, Denmark, 12 November 2024 – Novo Holdings, a leading global life science investor, today announced that it has co-led a $181.4 million Series D financing in Alentis Therapeutics (“Alentis”). […]

Read more

Novo Holdings invests in US$105 million Series C Funding of Alentis Therapeutics

/in

Alentis Therapeutics is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1) positive tumors Funding to advance clinical development of two first-in-class anti-CLDN1 antibodies and the platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodies Series C led by Jeito Capital together with Novo Holdings and RA Capital Management Naveed […]

Read more